489 related articles for article (PubMed ID: 25014522)
1. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
[TBL] [Abstract][Full Text] [Related]
2. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
[TBL] [Abstract][Full Text] [Related]
3. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
Ugajin M; Yamaki K; Hirasawa N; Yagi T
Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.
Müller B; Harbarth S; Stolz D; Bingisser R; Mueller C; Leuppi J; Nusbaumer C; Tamm M; Christ-Crain M
BMC Infect Dis; 2007 Mar; 7():10. PubMed ID: 17335562
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
Menéndez R; Martínez R; Reyes S; Mensa J; Filella X; Marcos MA; Martínez A; Esquinas C; Ramirez P; Torres A
Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of procalcitonin in community-acquired pneumonia.
Schuetz P; Suter-Widmer I; Chaudri A; Christ-Crain M; Zimmerli W; Mueller B;
Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
[TBL] [Abstract][Full Text] [Related]
7. The value of procalcitonin level in community-acquired pneumonia in the ED.
Park JH; Wee JH; Choi SP; Oh SH
Am J Emerg Med; 2012 Sep; 30(7):1248-54. PubMed ID: 22030193
[TBL] [Abstract][Full Text] [Related]
8. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia.
España PP; Capelastegui A; Bilbao A; Diez R; Izquierdo F; Lopez de Goicoetxea MJ; Gamazo J; Medel F; Salgado J; Gorostiaga I; Quintana JM;
Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3397-405. PubMed ID: 23010902
[TBL] [Abstract][Full Text] [Related]
9. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
10. Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot study.
Piacentini E; Sánchez B; Arauzo V; Calbo E; Cuchi E; Nava JM
J Crit Care; 2011 Apr; 26(2):201-5. PubMed ID: 20813489
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.
Kasamatsu Y; Yamaguchi T; Kawaguchi T; Tanaka N; Oka H; Nakamura T; Yamagami K; Yoshioka K; Imanishi M
Respirology; 2012 Feb; 17(2):330-6. PubMed ID: 22059525
[TBL] [Abstract][Full Text] [Related]
12. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis.
Hoshina T; Nanishi E; Kanno S; Nishio H; Kusuhara K; Hara T
J Infect Chemother; 2014 Oct; 20(10):616-20. PubMed ID: 25027057
[TBL] [Abstract][Full Text] [Related]
13. Procalcitonin kinetics in Legionella pneumophila pneumonia.
de Jager CP; de Wit NC; Weers-Pothoff G; van der Poll T; Wever PC
Clin Microbiol Infect; 2009 Nov; 15(11):1020-5. PubMed ID: 19438643
[TBL] [Abstract][Full Text] [Related]
14. Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ.
Krüger S; Ewig S; Kunde J; Hartmann O; Marre R; Suttorp N; Welte T;
Clin Chim Acta; 2010 Dec; 411(23-24):1929-34. PubMed ID: 20699094
[TBL] [Abstract][Full Text] [Related]
15. Utility of serum procalcitonin and C-reactive protein in severity assessment of community-acquired pneumonia in children.
Agnello L; Bellia C; Di Gangi M; Lo Sasso B; Calvaruso L; Bivona G; Scazzone C; Dones P; Ciaccio M
Clin Biochem; 2016 Jan; 49(1-2):47-50. PubMed ID: 26386341
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
17. Procalcitonin: inflammatory biomarker for assessing the severity of community-acquired pneumonia--a clinical observation in geriatric patients.
Heppner HJ; Bertsch T; Alber B; Esslinger AS; Dragonas C; Bauer JM; Sieber CC
Gerontology; 2010; 56(4):385-9. PubMed ID: 19940454
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia.
Horie M; Ugajin M; Suzuki M; Noguchi S; Tanaka W; Yoshihara H; Kawakami M; Kichikawa Y; Sakamoto Y
Am J Med Sci; 2012 Jan; 343(1):30-5. PubMed ID: 22207498
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia.
Lee JY; Hwang SJ; Shim JW; Jung HL; Park MS; Woo HY; Shim JY
Korean J Lab Med; 2010 Aug; 30(4):406-13. PubMed ID: 20805714
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
